MedTrace Logo

Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma

NCT02558894 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2018-08-02

Study results available
· View outcomes & findings →

Summary

A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Conditions

Interventions

DRUG

MEDI4736 monotherapy

MEDI4736 via IV infusion.

DRUG

tremelimumab+MEDI4736

tremelimumab+MEDI4736 via IV infusion.

Sponsors & Collaborators

Principal Investigators

  • Eileen M O'Reilly, M.D · Memorial Sloan Kettering Cancer Center, 300 East 66th Street,New York,NY 10065

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-16
Primary Completion
2017-06-15
Completion
2017-06-15
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Germany
  • Netherlands
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02558894 on ClinicalTrials.gov